A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy

Trial Profile

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Sep 2017

At a glance

  • Drugs ACE 083 (Primary)
  • Indications Facioscapulohumeral muscular dystrophy
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Acceleron Pharma
  • Most Recent Events

    • 03 Aug 2017 According to an Acceleron Pharma media release, the company expects to present results from all dose-escalation cohorts in part 1 in 2018.
    • 06 Jan 2017 According to an Acceleron Pharma media release, the company expects to present top-line results from the open label, dose-escalation part in late 2017 and initiate the randomized, double-blind, placebo-controlled stage of the study in 2018.
    • 29 Nov 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top